Martin F Bachmann

Summary

Affiliation: Cytos Biotechnology AG
Country: Switzerland

Publications

  1. ncbi The coming of age of virus-like particle vaccines
    Gary T Jennings
    Cytos Biotechnology AG, CH 8952 Zurich Schlieren, Switzerland
    Biol Chem 389:521-36. 2008
  2. ncbi Chemokines: more than just road signs
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Zurich Schlieren, Switzerland
    Nat Rev Immunol 6:159-64. 2006
  3. pmc A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice
    Gunther Spohn
    Cytos Biotechnology, Schlieren, Switzerland
    Virol J 7:146. 2010
  4. ncbi Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key
    Martin F Bachmann
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 34:317-26. 2004
  5. ncbi Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells
    Martin F Bachmann
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 173:2217-21. 2004
  6. pmc Interleukin 2: from immunostimulation to immunoregulation and back again
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Zurich Schlieren, Switzerland
    EMBO Rep 8:1142-8. 2007
  7. ncbi Therapeutic vaccination for chronic diseases: a new class of drugs in sight
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistr 25, Schlieren Zürich, Switzerland
    Nat Rev Drug Discov 3:81-8. 2004
  8. ncbi Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections
    Martin F Bachmann
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 37:1502-12. 2007
  9. ncbi Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation
    Martin F Bachmann
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 36:842-54. 2006
  10. doi Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
    Martin F Bachmann
    Research, Cytos Biotechnology AG, Wagistrasse 25, 8952 Schlieren Zürich, Switzerland
    Nat Rev Immunol 10:787-96. 2010

Collaborators

Detail Information

Publications94

  1. ncbi The coming of age of virus-like particle vaccines
    Gary T Jennings
    Cytos Biotechnology AG, CH 8952 Zurich Schlieren, Switzerland
    Biol Chem 389:521-36. 2008
    ..During the last decade, two prophylactic virus-like particle vaccines have been registered for human use, while another 12 vaccines entered clinical development...
  2. ncbi Chemokines: more than just road signs
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Zurich Schlieren, Switzerland
    Nat Rev Immunol 6:159-64. 2006
    ..Here, we propose that this dual function of chemokines ensures that T cells and dendritic cells meet in T-cell regions of lymphoid organs and that antigen is presented in an immunologically optimal context for T-cell priming...
  3. pmc A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice
    Gunther Spohn
    Cytos Biotechnology, Schlieren, Switzerland
    Virol J 7:146. 2010
    ..Although these vaccines were shown to protect from disease in animal models, multiple injections and/or strong adjuvants were required to reach efficacy, underscoring the need for more immunogenic, yet safe DIII-based vaccines...
  4. ncbi Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key
    Martin F Bachmann
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 34:317-26. 2004
    ..See accompanying article http://dx.doi.org/10.1002/eji.200324844..
  5. ncbi Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells
    Martin F Bachmann
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 173:2217-21. 2004
    ..Thus, Th cells but not CD40/CD40L are key for the differentiation of proliferation-competent central memory CD8(+) T cells...
  6. pmc Interleukin 2: from immunostimulation to immunoregulation and back again
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Zurich Schlieren, Switzerland
    EMBO Rep 8:1142-8. 2007
    ....
  7. ncbi Therapeutic vaccination for chronic diseases: a new class of drugs in sight
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistr 25, Schlieren Zürich, Switzerland
    Nat Rev Drug Discov 3:81-8. 2004
  8. ncbi Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections
    Martin F Bachmann
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 37:1502-12. 2007
    ..Thus, depending on the chronicity of antigen exposure, IL-2R signaling is either essential or largely dispensable for induction and maintenance of virus-specific CD8+ T cell responses...
  9. ncbi Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation
    Martin F Bachmann
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 36:842-54. 2006
    ....
  10. doi Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
    Martin F Bachmann
    Research, Cytos Biotechnology AG, Wagistrasse 25, 8952 Schlieren Zürich, Switzerland
    Nat Rev Immunol 10:787-96. 2010
    ..In this Review, we discuss the approaches currently being used to optimize the delivery of antigens and enhance vaccine efficacy...
  11. pmc Therapeutic vaccines for chronic diseases: successes and technical challenges
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Zuerich Schlieren, Switzerland
    Philos Trans R Soc Lond B Biol Sci 366:2815-22. 2011
    ..Here, we discuss several examples of vaccines that target these risk factors with the aim of preventing the associated diseases and some of the challenges they face...
  12. ncbi Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects
    Tazio Storni
    Cytos Biotechnology AG, Schlieren Zürich, Switzerland
    J Immunol 172:1777-85. 2004
    ..Thus, packaging CpGs into VLPs improves both their immunogenicity and pharmacodynamics...
  13. ncbi Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design
    Juliana Bessa
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 38:114-26. 2008
    ..Taken together, these results suggest that effective antibody-based vaccines are achievable by i.n. administration of Qbeta-VLP displaying specific antigens...
  14. ncbi Innate immunity together with duration of antigen persistence regulate effector T cell induction
    Tazio Storni
    Cytos Biotechnology, Schlieren Zürich, Switzerland
    J Immunol 171:795-801. 2003
    ..In contrast, Ag had to be presented for several days by activated APCs to trigger protective T cell responses. Thus, activation of APCs and duration of Ag presentation together regulate the induction of protective T cell responses...
  15. ncbi Limited in vivo reactivity of polyclonal effector cytotoxic T cells towards altered peptide ligands
    Patrick Bättig
    Cytos Biotechnology, AG Wagistrasse 25, 8952 Zurich Schlieren, Switzerland
    Microbes Infect 7:729-37. 2005
    ..Thus, effector functions induced by even highly homologous APLs are rather limited in vivo...
  16. pmc VSIG4, a B7 family-related protein, is a negative regulator of T cell activation
    Lorenz Vogt
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Clin Invest 116:2817-26. 2006
    ..The specific expression of VSIG4 on resting macrophages in tissue suggests that this inhibitory ligand may be important for the maintenance of T cell unresponsiveness in healthy tissues...
  17. doi Follicular and marginal zone B cells fail to cross-present MHC class I-restricted epitopes derived from viral particles
    Susanne A Keller
    Cytos Biotechnology AG, Schlieren, Switzerland
    J Immunol 182:6261-6. 2009
    ..This finding is of physiological importance because B cells with the ability to cross-present Ag to specific CD8(+) T cells may be killed by these cells, preventing the generation of neutralizing Ab responses...
  18. doi Mechanisms of allergen-specific desensitization
    Christina Uermösi
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Allergy Clin Immunol 126:375-83. 2010
    ..Although allergen-specific antibodies have an important role in the process, mechanisms of IgG-mediated inhibition of allergic reactions are not well defined...
  19. ncbi On the role of APC-activation for in vitro versus in vivo T cell priming
    Tazio Storni
    Cytos Biotechnology AG, Wagistr 25 8952, Schlieren Zürich, Switzerland
    Cell Immunol 225:1-11. 2003
    ..Thus, activation of professional APCs was mandatory for induction of effector CD8(+) T cell responses in vivo, while this step was largely dispensable in vitro...
  20. ncbi Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L
    Martin F Bachmann
    Cytos Biotechnology, Zurich Schlieren, Switzerland
    J Immunol 175:4686-96. 2005
    ....
  21. doi Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis
    Gunther Spohn
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 38:877-87. 2008
    ....
  22. doi Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation
    Susanne A Keller
    Cytos Biotechnology AG, Schlieren, Switzerland
    Eur J Immunol 40:103-12. 2010
    ..Thus, innate stimuli regulate cross-priming at the level of DC licensing for T-cell activation and not antigen presentation...
  23. doi Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner
    Juliana Bessa
    Cytos Biotechnology, Wagistrasse 25, Schlieren 8952, Switzerland
    J Immunol 184:4615-9. 2010
    ..Hence, IL-21 acts directly on B cells and cooperates with TLR signaling for optimal B cell responses...
  24. doi Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies
    Andrea Jegerlehner
    Cytos Biotechnology AG, Wagistr 25, 8952 Zurich Schlieren, Switzerland
    Vaccine 28:5503-12. 2010
    ....
  25. doi Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection
    Nicole Schmitz
    Cytos Biotechnology AG, Schlieren Zürich, Switzerland
    Eur J Immunol 42:863-9. 2012
    ..Hence, the innate immune system is required to direct isotype switching toward the more protective IgG2a/c antibodies...
  26. pmc Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein
    Roger R Beerli
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Schlieren, Switzerland
    Virol J 6:224. 2009
    ..Moreover, therapeutic treatment up to 2 days after infection was effective, suggesting that M2-specific monoclonals have a great potential as immunotherapeutic agents against Influenza infection...
  27. pmc Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy
    Nicole Schmitz
    Department of Immunodrugs, Cytos Biotechnology AG, 8952 Schlieren Zürich, Switzerland
    J Exp Med 206:1941-55. 2009
    ..Moreover, Qbeta-Fel d1 did not induce degranulation of basophils derived from human volunteers with cat allergies. These data suggest that vaccination with Qbeta-Fel d1 may be a safe and effective treatment for cat allergy...
  28. ncbi Rapid response of marginal zone B cells to viral particles
    Dominique Gatto
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 173:4308-16. 2004
    ....
  29. pmc Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells
    Caroline E von Allmen
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Schlieren, Switzerland
    Proc Natl Acad Sci U S A 106:11673-8. 2009
    ..Importantly, administration of a sPLA2-IID-Fc fusion protein inhibited disease development in murine models of colitis and multiple sclerosis, suggesting that sPLA2-IID's immunosuppressive function might be exploited therapeutically...
  30. doi Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles
    Susanne A Keller
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 184:26-9. 2010
    ..Thus, the presentation of viral particles to CD4(+) T cells is not restricted to distinct DC subsets, whereas the presentation of viral particles to CD8(+) T cells is limited to CD8(+) DCs...
  31. ncbi Role of Toll-like receptors in costimulating cytotoxic T cell responses
    Katrin Schwarz
    Cytos Biotechnology AG, Zurich, Switzerland
    Eur J Immunol 33:1465-70. 2003
    ..In contrast, stimulation of TLR9 dramatically increased CTL responses, indicating that ligands for TLR9 are likely to be the most promising candidates for the development of novel adjuvant formulations for stimulating CTL responses...
  32. doi Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses
    Juliana Bessa
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 183:3788-99. 2009
    ..Our data show that IgA switching is controlled differently according to the cell type receiving TLR signals. This knowledge should facilitate the development of IgA-inducing vaccines...
  33. ncbi Recall proliferation potential of memory CD8+ T cells and antiviral protection
    Martin F Bachmann
    Cytos Biotechnology, Zurich Schlieren, Switzerland
    J Immunol 175:4677-85. 2005
    ..These data indicate that the protective capacity of different subpopulations of memory T cells may vary dependent on the nature and the route of the challenge infection, which must be considered in T cell-based vaccine design...
  34. doi Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice
    Yu Zou
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Zurich, Schlieren, Switzerland
    Vaccine 28:3192-200. 2010
    ..Simultaneous immunization against IL-5 and eotaxin demonstrates that such a therapeutic approach may be used to treat complex disorders in which multiple mediators are involved...
  35. pmc Isolation of human monoclonal antibodies by mammalian cell display
    Roger R Beerli
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Schlieren, Switzerland
    Proc Natl Acad Sci U S A 105:14336-41. 2008
    ..The human nicotine-specific mAbs were validated preclinically in a mouse model. Thus, the technology presented here allows for rapid isolation of high-affinity, fully human antibodies with therapeutic potential from human volunteers...
  36. ncbi TLR9 signaling in B cells determines class switch recombination to IgG2a
    Andrea Jegerlehner
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 178:2415-20. 2007
    ..Thus, TLR9 can regulate isotype switching to IgG2a directly by interacting with B cells rather than indirectly by inducing Th1 responses...
  37. ncbi Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles
    Katrin Schwarz
    Cytos Biotechnology AG, Schlieren Zürich, Switzerland
    Eur J Immunol 35:816-21. 2005
    ..Thus, the use of VLP may avoid the requirement for complicated heterologous prime-boost regimens, facilitating the development of effective T cell-based vaccines...
  38. ncbi Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span
    Dominique Gatto
    Cytos Biotechnology, Zurich Schlieren, Switzerland
    J Immunol 178:67-76. 2007
    ....
  39. ncbi A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis
    Gunther Spohn
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 178:7450-7. 2007
    ....
  40. pmc Versatile virus-like particle carrier for epitope based vaccines
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    PLoS ONE 5:e9809. 2010
    ..Virus-like-particles are a very efficient means to confer high immunogenicity to antigens. We report here the development of virus-like-particles (VLPs) derived from the RNA bacteriophage AP205 for epitope-based vaccines...
  41. ncbi Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines
    Gary T Jennings
    Cytos Biotechnology AG, Wagistr 25, 8952 Zurich Schlieren, Switzerland
    Curr Mol Med 7:143-55. 2007
    ..Vaccines which, by way of rational design, incorporate viral properties to induce tailored responses and thus have the potential to provide safer and more effective prophylaxis and therapies...
  42. doi Innate immunity mediates follicular transport of particulate but not soluble protein antigen
    Alexander Link
    Cytos Biotechnology AG, 8952 Zurich Schlieren, Switzerland
    J Immunol 188:3724-33. 2012
    ..These findings identify size and repetitive structure as critical factors for efficient Ag presentation to B cells and highlight important differences between soluble proteins and viral particles...
  43. pmc Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies
    Christiane Ruedl
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Schlieren Zürich, Switzerland
    J Virol 79:717-24. 2005
    ..Thus, carrier suppression is unlikely to be a limiting factor for VLP-based T-cell vaccines...
  44. ncbi Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles
    Gunther Spohn
    Cytos Biotechnology, Zurich Schlieren, Switzerland
    J Immunol 175:6211-8. 2005
    ....
  45. ncbi Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP
    Christiane Ruedl
    Cytos Biotechnology AG, Schlieren Zürich, Switzerland
    Eur J Immunol 32:818-25. 2002
    ..In summary, the results show that VLP-derived epitopes are cross-presented by CD8(-) DC in vivo in a partial TAP-independent fashion and highlight important differences in the processing machinery of DC versus macrophages...
  46. ncbi A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses
    Andrea Jegerlehner
    Cytos Biotechnology AG, CH 8952 Schlieren Zurich, Switzerland
    Vaccine 20:3104-12. 2002
    ..This molecular assembly system may be used to induce strong B cell responses against most antigens...
  47. ncbi Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation
    Andrea Jegerlehner
    Cytos Biotechnology AG, Schlieren, Switzerland
    Eur J Immunol 32:3305-14. 2002
    ..Thus, IgG but not IgM responses are regulated by epitope density and B cell costimulatory thresholds...
  48. doi Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Lancet 371:821-7. 2008
    ..Immunisation against angiotensin II could solve this problem. We investigated the safety and efficacy of CYT006-AngQb-a vaccine based on a virus-like particle-that targets angiotensin II to reduce ambulatory blood pressure...
  49. ncbi Virus-like particles as a modular system for novel vaccines
    Franziska Lechner
    Cytos Biotechnology AG, Zurich, Switzerland
    Intervirology 45:212-7. 2002
    ..Using this method, efficient antibody responses may be induced in the absence of adjuvants resulting in protection from viral infection and allergic reactions...
  50. doi Identification of Ly-6K as a novel marker for mouse plasma cells
    Caroline E von Allmen
    Cytos Biotechnology AG, Wagistrasse 25, Schlieren, Switzerland
    Mol Immunol 45:2727-33. 2008
    ..This novel plasma cell marker shows promise to help broaden our understanding of plasma cell differentiation and function...
  51. doi A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain
    Till A Röhn
    Cytos Biotechnology AG, Immunodrugs, Zurich, Switzerland
    J Immunol 186:1769-80. 2011
    ..Thus, autovaccination targeting NGF using a VLP-based approach may represent a novel modality for the treatment of chronic pain...
  52. ncbi Heterogeneous antibody repertoire of marginal zone B cells specific for virus-like particles
    Dominique Gatto
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Zurich Schlieren, Switzerland
    Microbes Infect 9:391-9. 2007
    ..These results indicate that the response of MZ B cells to VLPs is clonotypically heterogeneous and suggest that the MZ B cell compartment is capable of generating variable and diverse antibody responses...
  53. ncbi A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity
    Patrik Maurer
    Cytos Biotechnology AG, Zurich, Switzerland
    Eur J Immunol 35:2031-40. 2005
    ..These data suggest that antibodies induced by NicQb may prevent relapses by sequestering nicotine in the blood of immunized smokers...
  54. doi Vaccines against non-communicable diseases
    Till A Röhn
    Cytos Biotechnology AG, Immunodrugs, Zurich, Switzerland
    Curr Opin Immunol 22:391-6. 2010
    ..Choice of the right target, proper vaccine design, optimal vaccine dose and regimen remain the major challenges to achieve clinical efficacy and safety for this novel class of biotherapeutics...
  55. ncbi Vaccination against nicotine: an emerging therapy for tobacco dependence
    Patrik Maurer
    Cytos Biotechnology, Wagistrasse 25, 8952 Schlieren, Zurich, Switzerland
    Expert Opin Investig Drugs 16:1775-83. 2007
    ..Antibody level dependence of abstinence was also observed with the nicotine vaccine NicVAX (Nabi Biopharmaceuticals). Vaccination against nicotine has the potential of becoming an important therapy against tobacco dependence...
  56. doi A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 43:716-22. 2013
    ..In summary, vaccination against IL-1α protected ApoE(-/-) mice against disease, suggesting that this may be a potential treatment option for atherosclerosis...
  57. doi Immunodrugs: therapeutic VLP-based vaccines for chronic diseases
    Gary T Jennings
    Cytos Biotechnology AG, Zurich Schlieren 8952, Switzerland
    Annu Rev Pharmacol Toxicol 49:303-26. 2009
    ..Safety study designs have considered the underlying B and T cell immunology and have examined potential toxicities of vaccine components and primary and secondary pharmacodynamic action of the vaccines...
  58. ncbi Rapid functional cloning of cell adhesion molecules
    Christiane Ruedl
    Cytos Biotechnology AG, Zurich, Switzerland
    Biotechniques 37:912, 914, 916. 2004
  59. doi T cell-dependent and -independent IgA responses: role of TLR signalling
    Juliana Bessa
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Zurich Schlieren, Switzerland
    Immunol Invest 39:407-28. 2010
    ..A better understanding of these mechanisms may facilitate the use of TLR agonists as adjuvants and consequently improve the development of effective mucosal vaccines...
  60. doi Immunization against angiotensins for the treatment of hypertension
    Patrik Maurer
    Cytos Biotechnology AG, Wagistr 25, CH 8952 Schlieren, Switzerland
    Clin Immunol 134:89-95. 2010
    ..It will also be important to ascertain whether the strong reduction of blood pressure in the early morning, when most cardiovascular events occur, might result in long-term benefits over current therapies...
  61. doi Exploiting viral properties for the rational design of modern vaccines
    Gunther Spohn
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Zurich Schlieren, Switzerland
    Expert Rev Vaccines 7:43-54. 2008
    ..As an elucidative example, this review will describe the key immunogenic determinants of viruses and discuss how they can be harnessed for the development of tailor-made vaccines against a wide array of human diseases...
  62. pmc Vaccination against GIP for the treatment of obesity
    Alma Fulurija
    Cytos Biotechnology AG, Schlieren, Switzerland
    PLoS ONE 3:e3163. 2008
    ..In fact GIP receptor-deficient mice (GIPR(-/-)) were shown to be completely protected from diet-induced obesity. Thus, disrupting GIP signaling represents a promising novel therapeutic strategy for the treatment of obesity...
  63. ncbi A second vaccine revolution for the new epidemics of the 21st century
    Mark R Dyer
    Cytos Biotechnology AG, Wagistr 25, 8952 Zurich Schlieren, Switzerland
    Drug Discov Today 11:1028-33. 2006
    ..A new class of medicines, based on vaccine approaches, are now in clinical trials and hold significant promise to treat both risk factors and their associated chronic diseases...
  64. ncbi Therapeutic vaccines for nicotine dependence
    Patrik Maurer
    Cytos Biotechnology AG, Wagistr 25, 8952 Zuerich Schlieren, Switzerland
    Curr Opin Mol Ther 8:11-6. 2006
    ..The first phase II clinical trial has confirmed the validity of the concept and shown that a vaccine against nicotine can be efficacious for smoking cessation in humans provided anti-nicotine antibody levels are sufficiently high...
  65. doi Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines
    Alexander Link
    Cytos Biotechnology AG, CH 8952 Zurich Schlieren, Switzerland
    Immunotherapy 2:561-74. 2010
    ..This article focuses on the tolerance mechanisms of the B- and T-cell compartments and how these may be manipulated to obtain high-affinity autoantibodies without inducing potentially dangerous autoreactive T-cell responses...
  66. ncbi Function of marginal zone B cells in antiviral B-cell responses
    Dominique Gatto
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Zurich Schlieren, Switzerland
    Crit Rev Immunol 25:331-42. 2005
    ..Herein, we review the current data on the functional characteristics that enable the MZ B-cell population to act as an efficient first line of defense against systemic infections...
  67. ncbi Hybrid Sindbis/Epstein-Barr virus episomal expression vector for inducible production of proteins
    Lidia Ivanova
    Cytos Biotechnology AG, Schlieren, Switzerland
    Biotechniques 39:209-12. 2005
    ..Moreover, protein production with selected cell populations could easily be scaled-up to a fermentation process...
  68. ncbi Immunotherapies: cause for measured optimism
    Gary T Jennings
    Cytos Biotechnology AG, Wagistr 25, CH 8952 Schlieren Zurich, Switzerland
    Drug Discov Today 7:994-6. 2002
  69. ncbi Balancing protective immunity and immunopathology
    Martin F Bachmann
    Cytos Biotechnology AG, Wagistrasse 25, Zurich, Schlieren Zürich, Switzerland
    Curr Opin Immunol 14:413-9. 2002
    ..In order to counterbalance overshooting immune responses, T cells and APCs secrete anti-inflammatory cytokines that are key for maintaining a healthy balance between protection and immunopathology...
  70. ncbi Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis
    Till A Röhn
    Cytos Biotechnology AG, Immunodrugs, Zurich, Switzerland
    Eur J Immunol 36:2857-67. 2006
    ..Active immunization against IL-17 therefore represents a novel therapeutic approach for the treatment of chronic inflammatory diseases...
  71. ncbi Enhanced apoptotic activity of a structurally optimized form of galectin-1
    Patrick Bättig
    Cytos Biotechnology AG, Wagistrasse 25, 8952 Schlieren Zürich, Switzerland
    Mol Immunol 41:9-18. 2004
    ..This structurally optimized form of galectin-1 may therefore be a potentially powerful tool to treat chronic inflammatory diseases...
  72. ncbi Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles
    Tazio Storni
    Cytos Biotechnology, AG, Department of Dermatology and Institute of Experimental Immunology, University Hospital, and Elektronenmikroskopisches Zentrallabor Universität, Zurich, Switzerland
    J Immunol 168:2880-6. 2002
    ..Thus, while VLPs alone are inefficient at inducing CTL responses, they become very powerful vaccines if applied together with substances that activate APCs...
  73. ncbi Therapeutic vaccination to block receptor-ligand interactions
    Gunther Spohn
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Zurich Schlieren, Switzerland
    Expert Opin Biol Ther 3:469-76. 2003
    ....
  74. ncbi Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection
    Manfred Kopf
    Molecular Biomedicine, Department of Environmental Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland
    Nat Med 8:373-8. 2002
    ..Consequently, T-helper cell-dependent IgG responses were reduced in C3-/- mice but remained intact in Cr2-/- mice. These results demonstrate that complement induces specific immunity by promoting T-cell responses...
  75. ncbi Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1
    Carsten Gründemann
    Department of Immunology, Institute of Medical Microbiology and Hygiene, University of Freiburg, Freiburg, Germany
    J Immunol 176:1311-5. 2006
    ..KLRG1 ligation by E-cadherin in healthy tissue may thus exert an inhibitory effect on primed T cells...
  76. ncbi Role of IgM antibodies versus B cells in influenza virus-specific immunity
    Manfred Kopf
    Swiss Federal Institute of Technology Zurich, Molecular Biomedicine, Department of Environmental Sciences, Zurich Schlieren, Switzerland
    Eur J Immunol 32:2229-36. 2002
    ..Taken together, our data suggest a role for B cells to promote effector T cell responses and a role of both IgM and IgG antibodies in the defense against acute influenza virus infection...
  77. ncbi Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity
    Andrea Jegerlehner
    Cytos Biotechnology, Schlieren, Switzerland
    J Immunol 172:5598-605. 2004
    ....
  78. ncbi Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein
    Giulia Freer
    Department of Experimental Pathology, University of Pisa, I 56127 Pisa, Italy
    Virology 322:360-9. 2004
    ..The data suggest that TrpM may not be a suitable target for antiviral vaccine design...
  79. ncbi Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults
    Thomas M Kundig
    University of Zurich, Department of Dermatology, University Hospital Zurich, Switzerland
    J Allergy Clin Immunol 117:1470-6. 2006
    ..In this study we covalently coupled a synthetic 16-amino-acid sequence of the allergen Der p 1 to a virus-like particle derived from the bacteriophage Qbeta (Qbeta-Der p 1)...
  80. ncbi A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity
    Patrice M Ambuhl
    Renal Division, University Hospital, Zurich, Switzerland
    J Hypertens 25:63-72. 2007
    ..Here we describe the preclinical development and the phase I clinical trial testing of a virus-like particle (VLP)-based antihypertensive vaccine...
  81. pmc Potent T cell agonism mediated by a very rapid TCR/pMHC interaction
    Jonathan M Boulter
    Department of Medical Biochemistry and Immunology, Cardiff University School of Medicine, Cardiff, UK
    Eur J Immunol 37:798-806. 2007
    ..The most striking feature of these data is that a very short half-life does not preclude the ability of a TCR/pMHC interaction to induce antiviral immunity, autoimmune disease and tumour rejection...
  82. pmc Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection
    Nicole Schmitz
    Molecular Biomedicine, ETH Zurich, Wagistrasse 27, 8952 Zurich, Switzerland
    J Virol 79:6441-8. 2005
    ..IL-1alpha/beta appear not to influence killing of virus-infected cells but to enhance IgM antibody responses and recruitment of CD4(+) T cells to the site of infection...
  83. ncbi CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells
    Benjamin J Marsland
    Molecular Biomedicine, Department of Environmental Sciences, Swiss Federal Institute of Technology, CH 8092 Zurich, Switzerland
    Immunity 22:493-505. 2005
    ....
  84. ncbi Regulation of homeostatic chemokine expression and cell trafficking during immune responses
    Scott N Mueller
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Science 317:670-4. 2007
    ..We propose that this transient chemokine modulation may help orchestrate local cellularity, thus minimizing competition for space and resources in activated lymphoid tissues...
  85. ncbi Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL
    Gunther Spohn
    Cytos Biotechnology, Zurich Schlieren, Switzerland
    Adv Exp Med Biol 602:135-42. 2007
  86. pmc Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1
    Dominique Gatto
    Cytos Biotechnology, Swiss Federal Institute of Technology, Zurich Schlieren 8952, Switzerland
    J Exp Med 201:993-1005. 2005
    ..These results suggest that complement receptors maintain antibody responses by delivery of differentiation and survival signals to precursors of bone marrow plasma cells...
  87. ncbi Osteopontin is not required for the development of Th1 responses and viral immunity
    Brian Abel
    Molecular Biomedicine, Swiss Federal Institute of Technology, and
    J Immunol 175:6006-13. 2005
    ..Contrary to a previous report, we found that OPN-/- mice mounted a normal immune response to Listeria monocytogenes. In conclusion, OPN is dispensable for antiviral immune responses against influenza virus and vaccinia virus...
  88. doi Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo
    Nancy Luckashenak
    Institute for Immunology, Ludwig Maximilian University, 80336 Munich, Germany
    Immunity 28:521-32. 2008
    ..Thus, our data demonstrate the importance of crosstolerance induction by DCs as a vital instrument for controlling self-reactive T cells from the peripheral repertoire and preventing autoimmune disease...
  89. doi Nanoparticles target distinct dendritic cell populations according to their size
    Vania Manolova
    Department Immunodrugs, Cytos Biotechnology, Schlieren, Switzerland
    Eur J Immunol 38:1404-13. 2008
    ..These data provide evidence that particle size determines the mechanism of trafficking to the LN and show that only small nanoparticles can specifically target LN-resident cells...
  90. pmc A vaccine against nicotine for smoking cessation: a randomized controlled trial
    Jacques Cornuz
    Department of Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland
    PLoS ONE 3:e2547. 2008
    ..A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period...
  91. pmc CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo
    Erika Schlaepfer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
    J Virol 78:12344-54. 2004
    ....
  92. ncbi Kinetic and mechanistic requirements for helping CD8 T cells
    Paola Agnellini
    Swiss Federal Institute of Technology, Institute for Microbiology, Wolfgang Pauli Strasse 10, Zurich, Switzerland
    J Immunol 180:1517-25. 2008
    ....
  93. ncbi Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison
    Tazio Storni
    Cytos Biotechnology, AG, Zurich, Switzerland
    J Immunol 172:6129-35. 2004
    ..Thus, Ag quantities required for cross-presentation and cross-priming are similar to those required for fueling the MHC class II pathway...
  94. pmc Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses
    Benjamin J Marsland
    Molecular Biomedicine, Swiss Federal Institute of Technology, Wagistrasse 27, CH 8952 Zurich Schlieren, Switzerland
    Proc Natl Acad Sci U S A 102:14374-9. 2005
    ..Our data show that increased activation signals delivered in vivo by highly activated dendritic cells, as present during viral infections, overcome the requirement for PKC- during CD8(+) T cell antiviral responses...